NKTX

+ Watchlist + Portfolio

Nkarta, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.54
52-Week Range: $1.70 – $3.72
Market Cap: $176.91M
P/E (TTM): —
EPS (TTM): -1.55
Dividend Yield: —

Advanced Metrics

Price/Book: 0.62
PEG Ratio: —
Return on Equity: -38.76%
Return on Assets: -19.57%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 7.98
Debt/Equity: 0.30
Total Debt: $73.54M
Free Cash Flow: $-55.13M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $67.69M

NKTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$90.90M	$96.77M	$96.74M	$90.43M
Selling, General & Admin	$28.06M	$34.88M	$31.45M	$31.57M
Operating Expenses	$118.95M	$131.65M	$128.19M	$122.00M
Operating Income	-$118.95M	-$131.65M	-$128.19M	-$122.00M
EBITDA	-$116.32M	-$125.78M	-$119.04M	-$112.80M
Pretax Income	-$113.84M	-$117.50M	-$108.79M	-$104.08M
Net Income	-$113.84M	-$117.50M	-$108.79M	-$104.08M
Diluted EPS	-2.61	-2.40	-1.60	-1.41
Diluted Shares	43.63M	49.01M	67.87M	73.99M

NKTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$37.49M	$31.04M	$27.87M	$39.63M
Current Assets	$360.69M	$253.07M	$273.34M	$282.51M
Total Assets	$472.94M	$378.88M	$501.20M	$404.21M
Current Liabilities	$22.05M	$23.33M	$18.92M	$22.27M
Total Debt	$82.93M	$88.34M	$80.27M	$76.42M
Total Liabilities	$100.73M	$105.60M	$93.23M	$91.88M
Retained Earnings	-$317.93M	-$435.43M	-$544.22M	-$648.31M
Shareholders' Equity	$372.21M	$273.29M	$407.98M	$312.32M
Working Capital	$338.64M	$229.74M	$254.42M	$260.25M

NKTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$57.00M	-$86.16M	-$99.70M	-$88.70M
Capital Expenditure	-$47.11M	-$28.15M	-$4.41M	-$1.21M
Free Cash Flow	-$104.11M	-$114.31M	-$104.11M	-$89.91M
Depreciation & Amortisation	$2.64M	$5.87M	$9.15M	$9.19M
Stock-Based Compensation	$16.86M	$17.20M	$16.73M	$8.56M
Investing Cash Flow	-$184.69M	$79.02M	-$129.56M	$100.32M
Financing Cash Flow	$219.01M	$691.00K	$226.08M	$141.00K
Net Change in Cash	-$22.68M	-$6.45M	-$3.17M	$11.76M

NKTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$24.17M	$20.78M	$20.20M	$25.28M	$24.99M
Selling, General & Admin	$12.39M	$6.41M	$7.09M	$5.68M	$5.89M
Operating Expenses	$36.56M	$27.19M	$27.29M	$30.96M	$30.88M
Operating Income	-$36.56M	-$27.19M	-$27.29M	-$30.96M	-$30.88M
EBITDA	-$34.27M	-$24.86M	-$24.98M	-$28.70M	-$28.54M
Pretax Income	-$31.98M	-$22.98M	-$21.71M	-$27.41M	-$27.83M
Net Income	-$31.98M	-$22.98M	-$21.71M	-$27.41M	-$27.83M
Diluted EPS	-0.43	-0.31	-0.29	-0.37	-0.37
Diluted Shares	73.92M	73.98M	74.02M	74.04M	74.26M

NKTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$52.60M	$53.41M	$60.11M	$39.63M	$27.36M
Current Assets	$271.55M	$296.57M	$289.27M	$282.51M	$235.88M
Total Assets	$470.61M	$448.31M	$427.24M	$404.21M	$372.07M
Current Liabilities	$18.76M	$18.93M	$18.99M	$22.27M	$18.21M
Total Debt	$78.91M	$78.54M	$76.63M	$76.42M	$75.00M
Total Liabilities	$91.80M	$90.64M	$89.34M	$91.88M	$86.21M
Retained Earnings	-$576.21M	-$599.18M	-$620.90M	-$648.31M	-$676.14M
Shareholders' Equity	$378.81M	$357.67M	$337.90M	$312.32M	$285.86M
Working Capital	$252.79M	$277.64M	$270.29M	$260.25M	$217.68M

NKTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$29.61M	-$18.75M	-$18.69M	-$21.65M	-$28.20M
Capital Expenditure	-$518.00K	-$138.00K	—	-$560.00K	-$413.00K
Free Cash Flow	-$30.13M	-$18.89M	-$18.68M	-$22.21M	-$28.61M
Depreciation & Amortisation	$2.30M	$2.33M	$2.31M	$2.26M	$2.34M
Stock-Based Compensation	$2.83M	$2.05M	$1.77M	$1.90M	$1.90M
Investing Cash Flow	$54.34M	$19.49M	$25.39M	$1.10M	$15.91M
Financing Cash Flow	$0.00	$77.00K	$0.00	$64.00K	$6.00K
Net Change in Cash	$24.73M	$816.00K	$6.70M	-$20.48M	-$12.28M

Market Snapshot

About

Nkarta, Inc. is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer treatment. The company focuses on creating allogeneic, off-the-shelf NK cell therapies using its proprietary cellular engineering platform.